Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki M. Stamatouli, Zoe Quandt, Ana Luisa Perdigoto et al. · Diabetes · 2018
Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two academic institutions and identified 27 patients in whom this developed, or an incidence of 0.9%. The patients had a variety of solid-organ cancers, but all had received either anti-PD-1 or anti-PD-L1 antibodies. Diabetes presented with ketoacidosis in 59%, and 42% had evidence of pancreatitis in the peridiagnosis period. Forty percent had at least one positive autoantibody and 21% had two or more. There was a predominance of HLA-DR4, which was present in 76% of patients. Other immune adverse events were seen in 70%, and endocrine adverse events in 44%. We conclude that autoimmune, insulin-dependent diabetes occurs in close to 1% of patients treated with anti-PD-1 or -PD-L1 CPIs. This syndrome has similarities and differences compared with classic type 1 diabetes. The dominance of HLA-DR4 suggests an opportunity to identify those at highest risk of these complications and to discover insights into the mechanisms of this adverse event.
Cited by 587 works. doi:10.2337/dbi18-0002
Authors
- Angeliki M. Stamatouli
- Zoe Quandt
- Ana Luisa Perdigoto
- Pamela L. Clark
- Harriet M. Kluger
- Sarah Ann Weiss
- Scott N. Gettinger
- Mario Sznol
- Arabella Young
- Robert J Rushakoff
- James Lee
- Jeffrey A. Bluestone
- Mark Stuart Anderson
- Kevan C. Herold
References
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody